[go: up one dir, main page]

IS2704B - Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini - Google Patents

Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini

Info

Publication number
IS2704B
IS2704B IS7766A IS7766A IS2704B IS 2704 B IS2704 B IS 2704B IS 7766 A IS7766 A IS 7766A IS 7766 A IS7766 A IS 7766A IS 2704 B IS2704 B IS 2704B
Authority
IS
Iceland
Prior art keywords
methylpyrazin
oxadiazol
sulfonamide
pyridin
methoxy
Prior art date
Application number
IS7766A
Other languages
English (en)
Other versions
IS7766A (is
Inventor
David William Tonge
Sian Tomiko Taylor
Francis Thomas Boyle
Andrew Mark Hughes
Donna Johnstone
Marianne Bernice Ashford
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7766A publication Critical patent/IS7766A/is
Publication of IS2704B publication Critical patent/IS2704B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7766A 2002-08-23 2005-03-22 Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini IS2704B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (en) 2002-08-23 2003-08-20 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

Publications (2)

Publication Number Publication Date
IS7766A IS7766A (is) 2005-03-22
IS2704B true IS2704B (is) 2010-12-15

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7766A IS2704B (is) 2002-08-23 2005-03-22 Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini

Country Status (31)

Country Link
US (2) US7820679B2 (is)
EP (2) EP1545710B1 (is)
JP (2) JP3663202B2 (is)
KR (1) KR20050035280A (is)
CN (1) CN100467023C (is)
AR (1) AR041037A1 (is)
AT (1) ATE427773T1 (is)
AU (1) AU2003255835B8 (is)
BR (1) BR0313655A (is)
CA (1) CA2496476C (is)
CL (1) CL2003001692A1 (is)
CY (1) CY1110712T1 (is)
DE (1) DE60327084D1 (is)
DK (1) DK1545710T3 (is)
ES (1) ES2323309T3 (is)
GB (1) GB0219660D0 (is)
IL (1) IL166730A0 (is)
IS (1) IS2704B (is)
MX (1) MXPA05001862A (is)
MY (2) MY136449A (is)
NO (1) NO330756B1 (is)
NZ (1) NZ538114A (is)
PL (1) PL375561A1 (is)
PT (1) PT1545710E (is)
RU (1) RU2340343C2 (is)
SA (1) SA03240363B1 (is)
SI (1) SI1545710T1 (is)
TW (1) TWI302912B (is)
UA (1) UA82071C2 (is)
WO (1) WO2004018044A2 (is)
ZA (1) ZA200501267B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
US20090062246A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Therapeutic treatment-014
NZ585310A (en) * 2007-10-12 2012-02-24 Astrazeneca Ab Composition 064
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
JP6113151B2 (ja) * 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물
JP2022520206A (ja) * 2019-02-12 2022-03-29 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー 微小血管狭心症

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (is) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (is) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
DK0755393T3 (da) * 1994-04-15 2001-12-17 Upjohn Co Nye krystalformer af 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazin
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
JP2002527378A (ja) 1998-10-15 2002-08-27 インペリアル・カレッジ・イノベイションズ・リミテッド 治療方法
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
EP1741713A3 (en) * 1999-12-15 2009-09-09 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
EP1256344B1 (en) * 2000-02-16 2006-12-20 Astellas Pharma Inc. Remedies for endothelin-induced diseases
MXPA02010764A (es) 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US6573285B2 (en) * 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
JP2005504721A (ja) 2001-03-06 2005-02-17 セレジィ ファーマシューティカルス， インコーポレイテッド 尿生殖障害の処置のための化合物および方法
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
EP1379238A1 (en) 2001-04-11 2004-01-14 Abbott Laboratories Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
AU2002355266A1 (en) 2001-07-23 2003-02-17 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
ATE498408T1 (de) 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
PT1761515E (pt) 2003-12-20 2009-02-11 Merck Patent Gmbh Derivados de tetra-hidroquinolina 2-(hetero)-aril substituídos
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
IS7766A (is) 2005-03-22
WO2004018044A2 (en) 2004-03-04
TW200409768A (en) 2004-06-16
UA82071C2 (en) 2008-03-11
CA2496476C (en) 2009-08-04
JP3663202B2 (ja) 2005-06-22
NO330756B1 (no) 2011-07-04
WO2004018044A3 (en) 2004-05-06
CA2496476A1 (en) 2004-03-04
PL375561A1 (en) 2005-11-28
TWI302912B (en) 2008-11-11
MXPA05001862A (es) 2005-06-03
EP1545710B1 (en) 2009-04-08
EP2072082A3 (en) 2009-12-23
JP2004083590A (ja) 2004-03-18
US7820679B2 (en) 2010-10-26
MY136449A (en) 2008-10-31
GB0219660D0 (en) 2002-10-02
NO20050689L (no) 2005-03-21
EP2072082A2 (en) 2009-06-24
KR20050035280A (ko) 2005-04-15
DK1545710T3 (da) 2009-06-29
ATE427773T1 (de) 2009-04-15
RU2005108349A (ru) 2005-08-27
WO2004018044A8 (en) 2004-06-24
DE60327084D1 (de) 2009-05-20
AU2003255835A1 (en) 2004-03-11
ES2323309T3 (es) 2009-07-13
JP2005097312A (ja) 2005-04-14
HK1077534A1 (en) 2006-02-17
IL166730A0 (en) 2006-01-15
AU2003255835B8 (en) 2007-05-17
PT1545710E (pt) 2009-05-26
AR041037A1 (es) 2005-04-27
AU2003255835B2 (en) 2007-04-05
ZA200501267B (en) 2006-10-25
RU2340343C2 (ru) 2008-12-10
SI1545710T1 (sl) 2009-08-31
EP1545710A2 (en) 2005-06-29
BR0313655A (pt) 2005-06-21
CN100467023C (zh) 2009-03-11
CL2003001692A1 (es) 2005-01-21
MY137595A (en) 2009-02-27
CN1688365A (zh) 2005-10-26
SA03240363B1 (ar) 2009-04-11
US20110003831A1 (en) 2011-01-06
NZ538114A (en) 2008-02-29
CY1110712T1 (el) 2015-06-10
US20060094729A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
EP1555267A4 (en) 2,3-dihydro-6-NITROIMIDAZOç2,1-b] oxazoles
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
CY1110712T1 (el) Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου
SI1663236T1 (sl) Kombinacija, ki obsega N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamid in bisfosfonat
PT102750A (pt) Geladeira portatil aperfeicoada
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
FR2840799B1 (fr) Vis d'osteosynthese
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
IS8072A (is) Miðlar úr bak kólesteról flutningi í meðferð á kólesterólhækkun
DK1553950T3 (da) Terapeutisk behandling
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
NO20040815L (no) Anvendelse av antroquinoner i behandling av nyresykdom.
NO20040935L (no) Plaster for behandling av dysfunksjoner og forstyrrelser i negler.
CY1105220T1 (el) Χρηση αναστολεων nf-κβ για την αγωγη των διαταραχων ξηροφθαλμιας
ES1051471Y (es) Sandalia multiforme perfeccionada
ITMI20022308A1 (it) Proteine per il trattamento di neutropenie.
ITRM20030427A1 (it) Tornitrice portatile, in particolare per la rettifica delle
ES1048785Y (es) Nevera portatil perfeccionada.
ES1051158Y (es) Monedero perfeccionado
ITRC20030003U1 (it) "portamonete"
SE0203450D0 (sv) Therapeutic heterocycles
SE0203451D0 (sv) Therapeutic Heterocycles